Study title: Schellong-G, Braemswig-J-H, Schwarze-E-W, Wannenmacher-M. Children's Hospital University of Muenster, FRG. An approach to reduce treatment and invasive staging in childhood Hodgkin's disease: the sequence of the German DAL multicenter studies. Bulletin du cancer, {Bull-Cancer}, 1988, vol. 75, no. 1, p. 41-51,Schellong-G, Braemswig-J-H, Schwarze-E-W, Wannenmacher-M. Children's Hospital University of Muenster, FRG. An approach to reduce treatment and invasive staging in childhood Hodgkin's disease: the sequence of the German DAL multicenter studies. Bulletin du cancer, {Bull-Cancer}, 1988, vol. 75, no. 1, p. 41-51,
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms [C04] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: PROCARBAZINE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |